Optimizing Patient Self-Management in Rheumatoid Arthritis: Strategies for Improved Adherence, Quality of Life, and Integrated Patient-Reported Outcomes: An Expert Interview with Dr. Allan Gibofsky
SmartMobile(TM)
Premiere Date: Wednesday, April 1, 2015This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Friday, April 1, 2016
Note: Credit Is No Longer Available
 | Allan Gibofsky, MD, JD, MACR, FACP, FCLM Professor of Medicine Weill Cornell Medicine Attending Rheumatologist Co-Director, Clinic for Inflammatory Arthritis Hospital for Special Surgery New York, NY |
There are three major domains of assessing efficacy in rheumatoid arthritis (RA): 1) signs and symptoms, 2) improvement in patient function, and 3) inhibition of structural progression. Accordingly, some assessment of patient-reported outcomes (PROs) is a necessary component of measuring RA activity. Nevertheless, clinicians rarely use formal assessment of PROs as part of routine clinical practice. Use of PROs may improve clinician and patient perspectives of disease status and achievable outcomes. One particular feature of PRO assessments is their ability to capture health-related quality of life (HRQoL) information, which can help clinicians determine treatment efficacy. Even with the benefits of knowing formal HRQoL data, many clinicians do not use these data in their management of patients with RA. In addition, many clinicians feel unprepared to successfully counsel patients to change their behaviors to self-monitor their status, adhere to medication, and exercise.
This CME Outfitters Expert Interview shares best practices, provides resources, and encourages clinicians to integrate evidence-based models, tools, and objective measures to optimize clinical outcomes in RA, such as reducing pain and disability.
This educational activity centers on the CMEO Make-One-Change Statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make-One-Change Statement for this activity is:
Incorporate patient-reported outcomes regarding health-related quality of life (HRQoL) in management of patients with rheumatoid arthritis.
At the end of this CE activity, participants should be able to:
- As part of daily clinical practice, outline and apply evidence-based models, tools, and objective measures to monitor and improve outcomes in patients with rheumatoid arthritis (RA).
- Integrate assessments of health-related quality of life (HRQoL) as a measure of RA health and disease progression and as a strategy to encourage patients with RA to make a “commitment to change” in current behaviors, such as in self-monitoring, adhering to medications, and exercising.
- Utilize patient-reported outcome (PRO) measures to identify the issues and outcomes that are of utmost concern for your patients with RA, to support improved shared decision-making and incorporation of HRQoL data into care across the continuum.
This activity is supported by an educational grant from AbbVie Inc.
Physicians, physician assistants, nurse practitioners, pharmacists, and other health care professionals treating patients with rheumatoid arthritis.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .25 contact hours (0.025 CEUs)
Universal Activity Number:
0376-0000-15-011-H01-P (recorded programs)
Activity Type: knowledge-based
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST4493 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.
Disclosure of Relevant Financial Relationships with Commercial Interests
CME Outfitters, LLC adheres to the ACCME Standards, as well as those of the ACPE, and CBRN, regarding commercial support of continuing medical education. It is the policy of CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Gibofsky has disclosed that is serves on the speakers bureau for AbbVie Inc.; Amgen Inc.; Antares Pharma; Celgene Corporation; Pfizer Inc.; and UCB, Inc. He serves as a consultant for AbbVie; Amgen Inc.; Antares Pharma; Celgene Corporation; Iroko Pharmaceuticals, LLC; Medac, Inc.; and Pfizer Inc. He holds stock in AbbVie Inc.; Amgen Inc.; GlaxoSmithKline; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc.; and Regeneron Pharmaceuticals, Inc.
Jeffrey Helfand, DO, MS (peer reviewer) has nothing to disclose.
France Daniel, MPH (planning committee) has nothing to disclose.
Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.
Sharon Tordoff, CCMEP (planning committee) has nothing to disclose.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, and AbbVie Inc do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
EI-002-040115-04
